2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progression

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 239-245

  Nakajima, Yuichi ^a   Madhyastha, Radha ^a   Maruyama, Masugi ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

2 Deoxy D ribose; 2 Deoxy L ribose; Angiogenesis; Hypoxia induced apoptosis; Invasion; Metastasis; Thymidine phosphorylase; Tumor microenvironment

Indexed keywords

2 DEOXY LEVO RIBOSE; 2 DEOXYRIBOSE; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; FLUOROURACIL; FOCAL ADHESION KINASE; GELATINASE B; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; VASCULOTROPIN; DEOXYRIBOSE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER INVASION; CELL INVASION; CELL MIGRATION; DNA DAMAGE; DRUG EFFICACY; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HYPOXIA; METASTASIS; MICROENVIRONMENT; NONHUMAN; OXIDATIVE STRESS; REVIEW; STEREOISOMERISM; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; DISEASE COURSE; DRUG ANTAGONISM; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYRIBOSE; DISEASE PROGRESSION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THYMIDINE PHOSPHORYLASE;

EID: 64049118395     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009787313846     Document Type: Review

References (92)

1. Desgranges, C.; Razaka, G.; Rabaud, M.; Picard, P.; Dupuch, F.; Bricaud, H. The human blood platelet: a cellular model to study the degradation of thymidine and its inhibition. Biochem. Pharmacol., 1982, 31(17), 2755-2759.
2. Friedkin, M.; Roberts, D. The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J. Biol. Chem., 1954, 207(1), 245-256.
3. Iltzsch, M.H.; el Kouni, M.H.; Cha, S. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry (Mosc). 1985, 24(24), 6799-6807.
4. Desgranges, C.; Razaka, G.; Rabaud, M.; Bricaud, H. Catabolism of thymidine in human blood platelets: purification and properties of thymidine phosphorylase. Biochim. Biophys. Acta, 1981, 654(2), 211-218.
5. Miyazono, K.; Okabe, T.; Urabe, A.; Takaku, F.; Heldin, C.H. Purification and properties of an endothelial cell growth factor from human platelets. J. Biol. Chem., 1987, 262(9), 4098-4103.
6. Asai, K.; Hirano, T.; Kaneko, S.; Moriyama, A.; Nakanishi, K.; Isobe, I.; Eksioglu, Y.Z.; Kato, T. A novel glial growth inhibitory factor, gliostatin, derived from neurofibroma. J. Neurochem., 1992, 59(1), 307-317.
7. Pauly, J.L.; Schuller, M.G.; Zelcer, A.A.; Kirss, T.A.; Gore, S.S.; Germain, M.J. Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients. J. Natl. Cancer Inst., 1977, 58(6), 1587-1590.
8. Ishikawa, F.; Miyazono, K.; Hellman, U.; Drexler, H.; Wernstedt, C.; Hagiwara, K.; Usuki, K.; Takaku, F.; Risau, W.; Heldin, C. H. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature, 1989, 338(6216), 557-562.
9. Miyadera, K.; Sumizawa, T.; Haraguchi, M.; Yoshida, H.; Konstanty, W.; Yamada, Y.; Akiyama, S. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/ thymidine phosphorylase. Cancer Res., 1995, 55(8), 1687-1690.
10. Moghaddam, A.; Zhang, H.T.; Fan, T.P.; Hu, D.E.; Lees, V.C.; Turley, H.; Fox, S.B.; Gatter, K.C.; Harris, A.L.; Bicknell, R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sci. USA, 1995, 92(4), 998-1002.
11. Haraguchi, M.; Miyadera, K.; Uemura, K.; Sumizawa, T.; Furukawa, T.; Yamada, K.; Akiyama, S.; Yamada, Y. Angiogenic activity of enzymes. Nature, 1994, 368(6468), 198.
12. Akiyama, S.; Furukawa, T.; Sumizawa, T.; Takebayashi, Y.; Nakajima, Y.; Shimaoka, S.; Haraguchi, M. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci., 2004, 95(11), 851-857.
13. Brown, N.S.; Bicknell, R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem. J., 1998, 334(Pt 1), 1-8.
14. Liekens, S.; Bronckaers, A.; Perez-Perez, M.J.; Balzarini, J. Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem. Pharmacol., 2007, 74(11), 1555-1567.
15. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 285(21), 1182-1186.
16. Folkman, J.; Merler, E.; Abernathy, C.; Williams, G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med., 1971, 133(2), 275-288.
17. Hlatky, L.; Hahnfeldt, P.; Folkman, J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst., 2002, 94(12), 883-893.
18. Weidner, N.; Semple, J.P.; Welch, W.R.; Folkman, J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N. Engl. J. Med., 1991, 324(1), 1-8.
19. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9(6), 669-676.
20. Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989, 246(4935), 1306-1309.
21. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219(4587), 983-985.
22. Jain, R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307(5706), 58-62.
23. Kerbel, R.; Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2002, 2(10), 727-739.
24. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature, 2005, 438(7070), 967-974.
25. Fernando, N.H.; Hurwitz, H.I. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist, 2004, 9(Suppl 1), 11-18.
26. Heist, R.S.; Fidias, P.; Huberman, M.; Ardman, B.; Sequist, L.V.; Temel, J.S.; Lynch, T.J. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J. Thorac. Oncol., 2008, 3(10), 1153-1158.
27. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer, 2006, 6(5), 392-401.
28. Lewis, C.; Murdoch, C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am. J. Pathol., 2005, 167(3), 627-635.
29. Matsushita, S.; Nitanda, T.; Furukawa, T.; Sumizawa, T.; Tani, A.; Nishimoto, K.; Akiba, S.; Miyadera, K.; Fukushima, M.; Yamada, Y.; Yoshida, H.; Kanzaki, T.; Akiyama, S. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res., 1999, 59(8), 1911-1916.
30. Matsuura, T.; Kuratate, I.; Teramachi, K.; Osaki, M.; Fukuda, Y.; Ito, H. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas. Cancer Res., 1999, 59(19), 5037-5040.
31. O'Byrne, K.J.; Koukourakis, M.I.; Giatromanolaki, A.; Cox, G.; Turley, H.; Steward, W.P.; Gatter, K.; Harris, A.L. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br. J. Cancer, 2000, 82(8), 1427-1432.
32. Takebayashi, Y.; Akiyama, S.; Akiba, S.; Yamada, K.; Miyadera, K.; Sumizawa, T.; Yamada, Y.; Murata, F.; Aikou, T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst., 1996, 88(16), 1110-1117.
33. Imazano, Y.; Takebayashi, Y.; Nishiyama, K.; Akiba, S.; Miyadera, K.; Yamada, Y.; Akiyama, S.; Ohi, Y. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J. Clin. Oncol., 1997, 15(7), 2570-2578.
34. Shimaoka, S.; Matsushita, S.; Nitanda, T.; Matsuda, A.; Nioh, T.; Suenaga, T.; Nishimata, Y.; Akiba, S.; Akiyama, S.; Nishimata, H. The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma. Cancer, 2000, 88(10), 2220-2227.
35. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature, 2005, 438(7070), 932-936.
36. Lewis, C.E.; Pollard, J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res., 2006, 66(2), 605-612.
37. Kumamoto, H.; Ooya, K. Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors. J. Oral Pathol. Med., 2006, 35(10), 606-612.
38. Sivridis, E.; Giatromanolaki, A.; Papadopoulos, I.; Gatter, K.C.; Harris, A.L.; Koukourakis, M. I. Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis. Br. J. Cancer, 2002, 86(9), 1465-1471.
39. Sivridis, E.; Giatromanolaki, A.; Anastasiadis, P.; Georgiou, L.; Gatter, K.C.; Harris, A.L.; Bicknell, R.; Koukourakis, M. I. Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. J. Pathol., 2002, 196(4), 416-422.
40. Tsukagoshi, S.; Saga, Y.; Suzuki, N.; Fujioka, A.; Nakagawa, F.; Fukushima, M.; Suzuki, M. Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo. Int. J. Oncol., 2003, 22(5), 961-967.
41. Zhang, J.; Mizoi, T.; Harada, N.; Shiiba, K.; Miyagawa, K.; Matsuno, S.; Sasaki, I. Thymidine phosphorylase expressed in macrophages enhances antitumor effect of 5′-deoxy-5-fluorouridine on human colorectal carcinoma cells. Anticancer Res., 2003, 23(1A), 323-329.
42. Yao, Y.; Kubota, T.; Sato, K.; Kitai, R. Macrophage infiltration-associated thymidine phosphorylase expression correlates with increased microvessel density and poor prognosis in astrocytic tumors. Clin. Cancer Res., 2001, 7(12), 4021-4026.
43. Brown, N.S.; Jones, A.; Fujiyama, C.; Harris, A.L.; Bicknell, R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res., 2000, 60(22), 6298-6302.
44. Gunningham, S.P.; Currie, M.J.; Morrin, H.R.; Tan, E.Y.; Turley, H.; Dachs, G.U.; Watson, A.I.; Frampton, C.; Robinson, B.A.; Fox, S. B. The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers. J. Pathol., 2007, 212(3), 335-344.
45. Watanabe, Y.; Nakai, H.; Ueda, H.; Nozaki, K.; Hoshiai, H.; Noda, K. Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer. Cancer Lett., 2003, 200(2), 173-176.
46. Sivridis, E.; Giatromanolaki, A.; Gatter, K.C.; Harris, A.L.; Koukourakis, M.I. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer, 2002, 95(5), 1055-1063.
47. Ueda, M.; Terai, Y.; Kumagai, K.; Ueki, K.; Kanemura, M.; Ueki, M. Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells. Int. J. Cancer, 2001, 91(6), 778-782.
48. Takao, S.; Akiyama, S. I.; Nakajo, A.; Yoh, H.; Kitazono, M.; Natsugoe, S.; Miyadera, K.; Fukushima, M.; Yamada, Y.; Aikou, T. uppression of metastasis by thymidine phosphorylase inhibitor. Cancer Res., 2000, 60(19), 5345-5348.
49. Sato, J.; Sata, M.; Nakamura, H.; Inoue, S.; Wada, T.; Takabatake, N.; Otake, K.; Tomoike, H.; Kubota, I. Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma. Int. J. Cancer, 2003, 106(6), 863-870.
50. Gotanda, T.; Haraguchi, M.; Tachiwada, T.; Shinkura, R.; Koriyama, C.; Akiba, S.; Kawahara, M.; Nishiyama, K.; Sumizawa, T.; Furukawa, T.; Mimata, H.; Nomura, Y.; Akiyama, S.; Nakagawa, M. Molecular basis for the involvement of thymidine phosphorylase in cancer invasion. Int. J. Mol. Med., 2006, 17(6), 1085-1091.
51. Ioachim, E. Thymidine phoshorylase expression in breast cancer: the prognostic significance and its association with other angiogenesis related proteins and extracellular matrix components. Histol. Histopathol., 2008, 23(2), 187-196.
52. Ioachim, E.; Charchanti, A.; Briasoulis, E.; Karavasilis, V.; Tsanou, H.; Arvanitis, D.L.; Agnantis, N.J.; Pavlidis, N. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur. J. Cancer, 2002, 38(18), 2362-2370.
53. Jones, J.L.; Walker, R.A. Control of matrix metalloproteinase activity in cancer. J. Pathol., 1997, 183(4), 377-379.
54. Legrand, C.; Gilles, C.; Zahm, J.M.; Polette, M.; Buisson, A.C.; Kaplan, H.; Birembaut, P.; Tournier, J.M. Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J. Cell Biol., 1999, 146(2), 517-529.
55. Sidenius, N.; Blasi, F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev., 2003, 22(2-3), 205-222.
56. Stevenson, D.P.; Milligan, S.R.; Collins, W.P. Effects of platelet-derived endothelial cell growth factor/thymidine phosphorylase, substrate, and products in a three-dimensional model of angiogenesis. Am. J. Pathol., 1998, 152(6), 1641-1646.
57. Hotchkiss, K.A.; Ashton, A.W.; Klein, R.S.; Lenzi, M.L.; Zhu, G.H.; Schwartz, E.L. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res., 2003, 63(2), 527-533.
58. Koshland, D.E. Jr.; Anderson, M.J. Effect of catabolite repression on chemotaxis in Salmonella typhimurium. Mol. Biol. Biochem. Biophys., 1980, 32136-143.
59. Strange, P.G.; Koshland, D.E. Jr. Receptor interactions in a signalling system: competition between ribose receptor and galactose receptor in the chemotaxis response. Proc. Natl. Acad. Sci. USA, 1976, 73(3), 762-766.
60. Zukin, R.S.; Hartig, P.R.; Koshland, D.E., Jr. Effect of an induced conformational change on the physical properties of two chemotactic receptor molecules. Biochemistry (Mosc)., 1979, 18(25), 5599-5605.
61. Hotchkiss, K.A.; Ashton, A.W.; Schwartz, E.L. Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. J. Biol. Chem., 2003, 278(21), 19272-19279.
62. Lahav, J.; Jurk, K.; Hess, O.; Barnes, M.J.; Farndale, R.W.; Luboshitz, J.; Kehrel, B.E. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood, 2002, 100(7), 2472-2478.
63. Yan, B.; Hu, D.D.; Knowles, S.K.; Smith, J.W. Probing chemical and conformational differences in the resting and active conformers of platelet integrin alpha(IIb)beta(3). J. Biol. Chem., 2000, 275(10), 7249-7260.
64. Seeliger, H.; Guba, M.; Koehl, G.E.; Doenecke, A.; Steinbauer, M.; Bruns, C.J.; Wagner, C.; Frank, E.; Jauch, K.W.; Geissler, E.K. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin. Cancer Res., 2004, 10(5), 1843-1852.
65. Yu, C.; Rahmani, M.; Dai, Y.; Conrad, D.; Krystal, G.; Dent, P.; Grant, S. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res., 2003, 63(8), 1822-1833.
66. Huang, C.; Li, J.; Ke, Q.; Leonard, S.S.; Jiang, B.H.; Zhong, X.S.; Costa, M.; Castranova, V.; Shi, X. Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C. Cancer Res., 2002, 62(20), 5689-5697.
67. Manickam, N.; Sun, X.; Li, M.; Gazitt, Y.; Essex, D.W. Protein disulphide isomerase in platelet function. Br. J. Haematol., 2008, 140(2), 223-229.
68. Deregibus, M.C.; Cantaluppi, V.; Calogero, R.; Lo Iacono, M.; Tetta, C.; Biancone, L.; Bruno, S.; Bussolati, B.; Camussi, G. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood, 2007, 110(7), 2440-2448.
69. Sengupta, S.; Sellers, L.A.; Matheson, H.B.; Fan, T.P. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. Br. J. Pharmacol., 2003, 139(2), 219-231.
70. Uchimiya, H.; Furukawa, T.; Okamoto, M.; Nakajima, Y.; Matsushita, S.; Ikeda, R.; Gotanda, T.; Haraguchi, M.; Sumizawa, T.; Ono, M.; Kuwano, M.; Kanzaki, T.; Akiyama, S. Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-L-ribose. Cancer Res., 2002, 62(10), 2834-2839.
71. Nakajima, Y.; Gotanda, T.; Uchimiya, H.; Furukawa, T.; Haraguchi, M.; Ikeda, R.; Sumizawa, T.; Yoshida, H.; Akiyama, S. Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose. Cancer Res., 2004, 64(5), 1794-1801.
72. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 1989, 49(23), 6449-6465.
73. Harris, A.L. Hypoxia--a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002, 2(1), 38-47.
74. Kitazono, M.; Takebayashi, Y.; Ishitsuka, K.; Takao, S.; Tani, A.; Furukawa, T.; Miyadera, K.; Yamada, Y.; Aikou, T.; Akiyama, S. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem. Biophys. Res. Commun., 1998, 253(3), 797-803.
75. Ikeda, R.; Furukawa, T.; Kitazono, M.; Ishitsuka, K.; Okumura, H.; Tani, A.; Sumizawa, T.; Haraguchi, M.; Komatsu, M.; Uchimiya, H.; Ren, X. Q.; Motoya, T.; Yamada, K.; Akiyama, S. Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose. Biochem. Biophys. Res. Commun., 2002, 291(4), 806-812.
76. Ikeda, R.; Che, X.F.; Ushiyama, M.; Yamaguchi, T.; Okumura, H.; Nakajima, Y.; Takeda, Y.; Shibayama, Y.; Furukawa, T.; Yamamoto, M.; Haraguchi, M.; Sumizawa, T.; Yamada, K.; Akiyama, S. 2-Deoxy-D-ribose inhibits hypoxia-induced apoptosis by suppressing the phosphorylation of p38 MAPK. Biochem. Biophys. Res. Commun., 2006, 342(1), 280-285.
77. Ikeda, R.; Furukawa, T.; Mitsuo, R.; Noguchi, T.; Kitazono, M.; Okumura, H.; Sumizawa, T.; Haraguchi, M.; Che, X.F.; Uchimiya, H.; Nakajima, Y.; Ren, X.Q.; Oiso, S.; Inoue, I.; Yamada, K.; Akiyama, S. Thymidine phosphorylase inhibits apoptosis induced by cisplatin. Biochem. Biophys. Res. Commun., 2003, 301(2), 358-363.
78. Jeung, H.C.; Che, X.F.; Haraguchi, M.; Zhao, H.Y.; Furukawa, T.; Gotanda, T.; Zheng, C.L.; Tsuneyoshi, K.; Sumizawa, T.; Roh, J. K.; Akiyama, S. Protection against DNA damage-induced apoptosis by the angiogenic factor thymidine phosphorylase. FEBS Lett., 2006, 580(5), 1294-1302.
79. Nakajima, Y.; Haraguchi, M.; Furukawa, T.; Yamamoto, M.; Nakanishi, H.; Tatematsu, M.; Akiyama, S. 2-Deoxy-L-ribose inhibits the invasion of thymidine phosphorylase-overexpressing tumors by suppressing matrix metalloproteinase-9. Int. J. Cancer, 2006, 119(7), 1710-1716.
80. Nishino, I.; Spinazzola, A.; Hirano, M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science, 1999, 283(5402), 689-692.
81. Kumagai, Y.; Sugiura, Y.; Sugeno, H.; Takebayashi, Y.; Takenoshita, S.; Yamamoto, T. Thymidine phosphorylase gene mutation is not a primary cause of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Intern. Med., 2006, 45(7), 443-446.
82. Haraguchi, M.; Tsujimoto, H.; Fukushima, M.; Higuchi, I.; Kuribayashi, H.; Utsumi, H.; Nakayama, A.; Hashizume, Y.; Hirato, J.; Yoshida, H.; Hara, H.; Hamano, S.; Kawaguchi, H.; Furukawa, T.; Miyazono, K.; Ishikawa, F.; Toyoshima, H.; Kaname, T.; Komatsu, M.; Chen, Z.S.; Gotanda, T.; Tachiwada, T.; Sumizawa, T.; Miyadera, K.; Osame, M.; Noda, T.; Yamada, Y.; Akiyama, S. Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice. Mol. Cell. Biol., 2002, 22(14), 5212-5221.
83. Sui, L.; Dong, Y.; Watanabe, Y.; Yamaguchi, F.; Hatano, N.; Izumori, K.; Tokuda, M. Growth inhibitory effect of D-allose on human ovarian carcinoma cells in vitro. Anticancer Res., 2005, 25(4), 2639-2644.
84. Yamaguchi, F.; Takata, M.; Kamitori, K.; Nonaka, M.; Dong, Y.; Sui, L.; Tokuda, M. Rare sugar D-allose induces specific up-regulation of TXNIP and subsequent G1 cell cycle arrest in hepatocellular carcinoma cells by stabilization of p27kip1. Int. J. Oncol., 2008, 32(2), 377-385.
85. Ahmad, I.M.; Abdalla, M.Y.; Aykin-Burns, N.; Simons, A.L.; Oberley, L.W.; Domann, F.E.; Spitz, D.R. 2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress. Free Radic. Biol. Med., 2008, 44(5), 826-834.
86. Maschek, G.; Savaraj, N.; Priebe, W.; Braunschweiger, P.; Hamilton, K.; Tidmarsh, G.F.; De Young, L.R.; Lampidis, T.J. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res., 2004, 64(1), 31-34.
87. Varshney, R.; Dwarakanath, B.; Jain, V. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int. J. Radiat. Biol., 2005, 81(5), 397-408.
88. Zhang, X.D.; Deslandes, E.; Villedieu, M.; Poulain, L.; Duval, M.; Gauduchon, P.; Schwartz, L.; Icard, P. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res., 2006, 26(5A), 3561-3566.
89. Maher, J.C.; Wangpaichitr, M.; Savaraj, N.; Kurtoglu, M.; Lampidis, T.J. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol. Cancer Ther., 2007, 6(2), 732-741.
90. Kurtoglu, M.; Gao, N.; Shang, J.; Maher, J.C.; Lehrman, M.A.; Wangpaichitr, M.; Savaraj, N.; Lane, A.N.; Lampidis, T.J. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther., 2007, 6(11), 3049-3058.
91. Emura, T.; Suzuki, N.; Yamaguchi, M.; Ohshimo, H.; Fukushima, M. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int. J. Oncol., 2004, 25(3), 571-578.
92. Temmink, O.H.; Hoebe, E.K.; Fukushima, M.; Peters, G.J. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur. J. Cancer, 2007, 43(1), 175-183.